APTOSE BIOSCIENCES INC. Table of Contents As filed with the Securities and Exchange Commission on December 29, 2023 Registration No. 333-275870 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO.2 To FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aptose Biosciences U.S. Inc. Unit 120, 12770 High Bluff Drive San Diego, California 92130 (858) 926-2730 (Name, address, including zip code, and telephone number, including area code, of agent for service) COPIES ...

Table of Contents As filed with the Securities and Exchange Commission on December 11, 2023 Registration No. 333-275870 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO.1 To FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTOSE BIOSCIENCES INC. (Exact Name of Registrant As Specified In Its Charter) (State or other jurisdiction of incorporation or organization) Canada 2836 98-1136802 (Primary Standard Industrial Classification Code Number) (I.R.S. Employe ...

Table of Contents As filed with the Securities and Exchange Commission on December 1, 2023 Registration No. 333-________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTOSE BIOSCIENCES INC. (Exact Name of Registrant As Specified In Its Charter) (State or other jurisdiction of incorporation or organization) Canada 2836 98-1136802 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification ...

Aptose Biosciences Inc. (NASDAQ:APTO) Q3 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Susan Pietropaolo - Managing Director-Corporate Communications & Investor Relations William Rice - Chairman, President & Chief Executive Officer Rafael Bejar - Senior Vice President & Chief Medical Officer Conference Call Participants John Newman - Canaccord Genuity Operator Good afternoon. My name is Hope, and I will be your conference operator today. I would like to welcome everyone to t ...

Financial Performance - The net loss for the nine months ended September 30, 2023, was $39,252,000, compared to a net loss of $31,823,000 for the same period in 2022, indicating a 23.2% increase in losses[20]. - For the three months ended September 30, 2023, the net loss was $11.447 million compared to a net loss of $9.777 million for the same period in 2022, representing a 16.9% increase in losses[27]. - The company reported total comprehensive loss of $39,249,000 for the nine months ended September 30, 2023, compared to $31,840,000 for the same period in 2022[20]. - The net loss for the three months ended September 30, 2023, was $11,447,000, compared to a net loss of $9,777,000 for the same period in 2022, reflecting an increase in losses of 17%[20]. - The company recorded a loss per share of $6.14 for the nine months ended September 30, 2023, compared to a loss per share of $5.17 for the same period in 2022[75]. Assets and Liabilities - Total assets decreased from $51,027,000 as of December 31, 2022, to $20,876,000 as of September 30, 2023, representing a decline of approximately 59%[12][14]. - Total liabilities remained relatively stable, decreasing slightly from $13,286,000 to $13,100,000[15]. - Total shareholders' equity decreased significantly from $37,741,000 as of December 31, 2022, to $7,776,000 as of September 30, 2023, a decline of approximately 79.4%[17]. - The company’s working capital as of September 30, 2023, was approximately $7.3 million, down from $37.2 million as of December 31, 2022[36]. - Cash and cash equivalents dropped from $36,970,000 to $15,720,000, a decrease of about 57.6%[12]. Cash Flow and Financing - Cash used in operating activities for the nine months ended September 30, 2023, was $35.331 million, up from $23.671 million in the same period of 2022, indicating a 49.4% increase in cash outflow[27]. - The company plans to raise additional funds through equity financing under the 2022 ATM Facility, 2023 Committed Equity Facility, and the Hanmi Subscription Agreement to support operations[36]. - The company expects to continue experiencing negative cash flow from operations until regulatory approval is received for its product candidates[34]. - The company is evaluating strategies to obtain additional funding, including equity financing and restructuring operations to decrease expenses[40]. - The company’s current cash and cash equivalents are projected to support operations through March 2024, raising substantial doubt about its ability to continue as a going concern[33]. Research and Development - Research and development expenses for the three months ended September 30, 2023, were $8,256,000, up 25.5% from $6,578,000 for the same period in 2022[20]. - The company recognized $3.1 million in expenses related to the supply agreement with Hanmi for the nine months ended September 30, 2023[64]. - Supply costs paid to Hanmi amounted to $4.5 million for the nine months ended September 30, 2023, compared to nil in the same period of 2022[65]. - The company has two clinical-stage investigational products for hematological malignancies: tuspetinib and luxeptinib[32]. Shareholder Equity and Stock Options - The company issued 668,000 common shares under the Hanmi Subscription Agreement, raising $3,000,000[23]. - The weighted average number of common shares outstanding increased from 6,153,000 in Q3 2022 to 6,495,000 in Q3 2023[20]. - The Company granted 217 stock options during the nine months ended September 30, 2023, with a weighted average exercise price of $9.87[90]. - The Company issued a total of 328,438 Common Shares to Keystone at an average price of $3.5 per share, raising cash proceeds of $1.15 million as of September 30, 2023[70]. - The Company raised a total of $1.94 million in cash proceeds from issuing Common Shares under the 2022 ATM Facility as of September 30, 2023[72].

Aptose Biosciences Inc. (NASDAQ:APTO) Q2 2023 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants Susan Pietropaolo - Corporate Communications and Investor Relations William Rice - Chairman, President and Chief Executive Officer Rafael Bejar - Senior Vice President and Chief Medical Officer Fletcher Payne - Senior Vice President and Chief Financial Officer Conference Call Participants Edward Tenthoff - Piper Sandler Matthew Biegler - Oppenheimer Li Watsek - Cantor Fitzgerald Soumit Roy ...

Financial Performance - The net loss for the three months ended June 30, 2023, was $14,129 thousand, compared to a net loss of $10,565 thousand for the same period in 2022, indicating a 34% increase in losses [19]. - The net loss for the six months ended June 30, 2023, was $27.81 million, compared to a net loss of $22.05 million for the same period in 2022, indicating a 26% increase in losses [19]. - Basic and diluted loss per common share for the three months ended June 30, 2023, was $2.27, compared to $1.72 for the same period in 2022, reflecting a 32% increase in loss per share [19]. - The company reported a net loss per share of $4.47 for the six months ended June 30, 2023, compared to $3.59 for the same period in 2022, indicating a worsening loss per share [62]. - The company reported total operating expenses of $14,452 thousand for the three months ended June 30, 2023, which is a 35% increase from $10,673 thousand in the same period of 2022 [19]. Assets and Liabilities - Total assets decreased from $51,027 thousand as of December 31, 2022, to $26,575 thousand as of June 30, 2023, representing a decline of approximately 48% [16]. - Total current assets decreased from $49.52 million as of December 31, 2022, to $25.26 million as of June 30, 2023, a decline of 49% [15]. - Total liabilities decreased slightly from $13,286 thousand as of December 31, 2022, to $12,789 thousand as of June 30, 2023, a reduction of approximately 4% [16]. - Shareholders' equity fell from $37,741 thousand to $13,786 thousand, a decline of about 64% [16]. - Cash and cash equivalents dropped significantly from $36,970 thousand to $8,400 thousand, a decrease of about 77% [15]. Cash Flow and Funding - The company used $13.5 million in operating activities during the three months ended June 30, 2023, compared to $7.0 million in the same period in 2022 [25]. - The company utilized $24.8 million in cash for operating activities during the six months ended June 30, 2023, compared to $16.7 million for the same period in 2022 [25]. - The company plans to raise additional funds to support its operations, but there is no assurance that such funds will be available on acceptable terms [29]. - The company is evaluating strategies to obtain additional funding for future operations due to substantial doubt about its ability to continue as a going concern [36]. - The company has entered into a committed equity facility with Keystone Capital Partners, allowing for the sale of up to $25.0 million of common shares over a 24-month term [58]. Research and Development - Research and development expenses for the three months ended June 30, 2023, were $10,582 thousand, up 44% from $7,341 thousand in the same period of 2022 [19]. - The company has two clinical-stage investigational products for hematological malignancies: tuspetinib and luxeptinib [28]. - The company expects negative cash flow to continue until regulatory approval is received for its products or revenue exceeds expenses [30]. Stock and Equity - The company issued common shares under the 2022 ATM Facility, raising $1.1 million during the three months ended June 30, 2023 [25]. - A reverse stock split at a ratio of 1-for-15 was approved and took effect on June 6, 2023 [33]. - The company granted 215,000 stock options during the six months ended June 30, 2023, with a weighted average exercise price of $9.93 [68]. - The company recorded share-based payment expense of $2,643,000 for the six months ended June 30, 2023, down from $3,293,000 in the same period of 2022, reflecting a 20% decrease [79]. - The company has a maximum of 113,333 common shares available for sale under the Employee Stock Purchase Plan (ESPP) [67]. Accumulated Deficit - As of June 30, 2023, the company reported an accumulated deficit of approximately $492.1 million, up from $464.3 million as of December 31, 2022 [32]. - The company had working capital of approximately $13.3 million as of June 30, 2023, down from $37.2 million as of December 31, 2022 [32]. - Accrued liabilities increased to $8.084 million as of June 30, 2023, compared to $5.657 million on December 31, 2022 [51].

As filed with the Securities and Exchange Commission on June 28, 2023 Registration No. 333-272752 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTOSE BIOSCIENCES INC. (Exact Name of Registrant As Specified In Its Charter) | Canada | 2836 | 98-1136802 | | --- | --- | --- | | (State or other jurisdiction of incorporation or | (Primary Standard Industrial | (I.R.S. Employer | | organization) | Classif ...

As filed with the Securities and Exchange Commission on June 16, 2023 Registration No. 333-________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Aptose Biosciences U.S. Inc. Unit 120, 12770 High Bluff Drive San Diego, California 92130 (858) 926-2730 (Name, address, including zip code, and telephone number, including area code, of agent for service) FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTOSE BIOSCIENCES INC. (Exact Name of Registrant As Specified In Its ...

Aptose Biosciences Inc. (NASDAQ:APTO) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Susan Pietropaolo – Corporate Communications & Investor Relations William G. Rice – Chairman, President and Chief Executive Officer Rafael Bejar – Senior Vice President and Chief Medical Officer Fletcher Payne – Senior Vice President and Chief Financial Officer Conference Call Participants Edward Tenthoff – Piper Sandler & Co. Li Watsek – Cantor Fitzgerald Joseph Pantginis – H.C. Wainwright Ope ...